Ohio is currently home to 3201 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, North Canton, Ohio
Conditions: Generalized Anxiety Disorder
Register for Updates
Study of Olutasidenib and Temozolomide in HGG
NCT06161974
Recruiting
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
02/19/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Register for Updates
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT05786040
Recruiting
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. Tafasitamab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Register for Updates
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
NCT06269978
Recruiting
This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Colorectal Cancer AJCC v8
Register for Updates
Perceptions of E-Cigarettes and Synthetic Cooling Agents, the ICE Study
NCT06208202
Recruiting
This study evaluates how synthetic cooling additives like WS-3 and WS-23 impact e-cigarette perceptions, use behavior, and toxicant exposure.
Gender:
ALL
Ages:
Between 21 years and 29 years
Trial Updated:
02/18/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Abuse Tobacco, Exposure
Register for Updates
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients with Suspected Coronary Ischemia.
NCT05868902
Recruiting
A multicenter observational data development registry collecting diagnostic measures via standard of care (SOC) cardiac PET in order gain a better understanding of how CardioFlux MCG may be used in the detection of coronary ischemia.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/18/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Coronary; Ischemic
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: The Cleveland Clinic Foundation DBA Cleveland Clinic Lerner College of Medicine, Celveland, Ohio
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Uncertainty and Firearms: Obtaining Secure Storage
NCT05818696
Recruiting
The goal of this clinical trial is to test whether inclusion of cognitive behavioral therapy (CBT) for Uncertainty-Enhanced (CUE) with Lethal Means Counseling (LMC) is acceptable, feasible, and efficacious in addressing secure firearm storage and associated psychological constructs in active duty servicemembers. The clinical trial aims to: * Assess the preliminary efficacy of a LMC intervention, augmented with CUE, on firearm storage practices * Examine mechanisms through which CUE and LMC incr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Ohio State University Department of Psychiatry and Behavioral Health, Columbus, Ohio
Conditions: Anxiety
Register for Updates
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
Recruiting
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: UH Geauga Medical Center, Chardon, Ohio
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Register for Updates
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/18/2025
Locations: Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio
Conditions: Asthma
Register for Updates
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
ALL
Ages:
Between 1 day and 30 days
Trial Updated:
02/18/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Congenital Heart Disease in Children
Register for Updates
Regional Phenotyping of CF and Non-CF Bronchiectasis
NCT04793867
Recruiting
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
02/18/2025
Locations: Penny New, Cincinnati, Ohio
Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Register for Updates